Search results for "Nephrocalcinosis"

showing 6 items of 6 documents

Renal involvement in psychological eating disorders

2011

Psychological eating disorders – anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder – are an increasing public health problem with severe clinical manifestations: hypothermia, hypotension, electrolyte imbalance, endocrine disorders and kidney failure; they are of interest to nephrologists, but pathophysiological mechanisms in determining the renal involvement are still unclear. We describe pathophysiology, histological features and clinical manifestations of the most frequent psychological eating disorders: AN and BN. Regarding AN, we analyze the recent literature, and identify 3 principal pathways towards renal involvement: chronic dehydration-hypokalemia, nephrocalcinosis …

MaleNephrologymedicine.medical_specialtyAnorexia NervosaHypokalemiaBioinformaticsRhabdomyolysisAdipokinesBinge-eating disorderInternal medicineAnimalsHumansMedicineObesityBulimiaInflammationDehydrationGlomerulosclerosis Focal Segmentalbusiness.industryBulimia nervosaBulimia Nervosa.Acute kidney injuryGeneral MedicineKidney diseasemedicine.diseaseKidney diseases; Anorexia Nervosa; Bulimia Nervosa.NephrocalcinosisEating disordersEndocrinologyNephrologyAnorexia nervosa (differential diagnoses)CytokinesIntercellular Signaling Peptides and ProteinsFemaleKidney DiseasesNephrocalcinosisbusinessKidney disease
researchProduct

AICA-ribosiduria due to ATIC deficiency: Delineation of the phenotype with three novel cases, and long-term update on the first case.

2020

5-Amino-4-imidazolecarboxamide-ribosiduria (AICA)-ribosiduria is an exceedingly rare autosomal recessive condition resulting from the disruption of the bifunctional purine biosynthesis protein PURH (ATIC), which catalyzes the last two steps of de novo purine synthesis. It is characterized biochemically by the accumulation of AICA-riboside in urine. AICA-ribosiduria had been reported in only one individual, 15 years ago. In this article, we report three novel cases of AICA-ribosiduria from two independent families, with two novel pathogenic variants in ATIC. We also provide a clinical update on the first patient. Based on the phenotypic features shared by these four patients, we define AICA-…

Hydroxymethyl and Formyl TransferasesMalemedicine.medical_specialtyCyclohydrolase activityBioinformaticsCongenital AbnormalitiesEpilepsyMultienzyme ComplexesIntellectual DisabilityGeneticsmedicineHumansBifunctional Purine Biosynthesis Protein PURHChildGenetics (clinical)ATIC DEFICIENCYEpilepsybusiness.industryInfant NewbornInfantmedicine.diseaseAminoimidazole CarboxamidePhenotypePhenotypeNucleotide DeaminasesChild PreschoolMutationMedical geneticsFemaleRibonucleosidesNephrocalcinosisbusinessRare diseaseJournal of inherited metabolic diseaseREFERENCES
researchProduct

The Relationship of Amelogenesis Imperfecta and Nephrocalcinosis Syndrome

2008

Aim: To analyze the prevalence and associated oral findings of nephrocalcinosis in a group of patients affected with amelogenesis imperfecta (AI). The relationship between types of AI and nephrocalcinosis were also evaluated. Design: This study examines patients who were referred to Pediatric Dentistry Department of SDU between the years of 2002-2007 and who, upon clinical and radiological examination, were diagnosed with AI and treated. Patients were offered information about the possibility of nephrocalcinosis syndrome. Patients who agreed to have tests carried out on their renal system were advised to visit the department of nephrology at the clinic. Results: Suspicious radiopacity was o…

Nephrologymedicine.medical_specialtyPediatricsAdolescentAmelogenesis ImperfectaCalcinosisInternal medicinePrevalenceHumansMedicineAmelogenesis imperfectaChildGeneral Dentistrybusiness.industrySyndromeHyperplasiaPulp stonemedicine.diseaseDelayed eruption:CIENCIAS MÉDICAS [UNESCO]SurgeryNephrocalcinosisRenal FindingsOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryNephrocalcinosisbusiness
researchProduct

Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants

2020

Overlapping syndromes such as Noonan, Cardio-Facio-Cutaneous, Noonan syndrome (NS) with multiple lentigines and Costello syndromes are genetically heterogeneous conditions sharing a dysregulation of the RAS/mitogen-activated protein kinase (MAPK) pathway and are known collectively as the RASopathies. PTPN11 was the first disease-causing gene identified in NS and remains the more prevalent. We report seven patients from three families presenting heterozygous missense variants in PTPN11 probably responsible for a disease phenotype distinct from the classical Noonan syndrome. The clinical presentation and common features of these seven cases overlap with the SHORT syndrome. The latter is the c…

Malemusculoskeletal diseases0301 basic medicineMAPK/ERK pathwaycongenital hereditary and neonatal diseases and abnormalitiesMAP Kinase Signaling SystemProtein Tyrosine Phosphatase Non-Receptor Type 11030105 genetics & heredityBiologyGene productPhosphatidylinositol 3-Kinases03 medical and health sciencesMetabolic DiseasesGeneticsmedicineHumansMissense mutationskin and connective tissue diseasesProtein kinase BGrowth DisordersGenetics (clinical)GeneticsGenetic heterogeneityNoonan SyndromeGenetic Variationmedicine.diseasePTPN11NephrocalcinosisPhenotype030104 developmental biologySHORT syndromeHypercalcemiaNoonan syndromeFemaleMitogen-Activated Protein KinasesSignal TransductionClinical Genetics
researchProduct

Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: r…

2020

Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with response. The prognostic role of hypomagnesemia during bevacizumab treatment has not been studied yet. Here, we evaluate the prognostic value of hypomagnesemia in patients with metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab as first-line therapy. A total of 391 of 752 patients of the firstline irinotecan study population had magnesium levels measured a…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyRenal Tubular Transport Inborn ErrorsBevacizumabSide effectColorectal cancerHypercalciuriaLeucovorinCetuximabIrinotecanGastroenterologyHypomagnesemia03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)MagnesiumAgedRetrospective StudiesPharmacologyCetuximabbusiness.industryHazard ratiomedicine.diseasePrognosisIrinotecanBevacizumabSurvival RateNephrocalcinosis030104 developmental biologyOncology030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnti-cancer drugs
researchProduct

Osteitis fibrosa cystica

2016

Joint Bone Spine - In Press.Proof corrected by the author Available online since vendredi 27 mai 2016

Malemedicine.medical_specialtyTreatment outcomeMEDLINEOsteitis fibrosa cysticaOsteitis Fibrosa Cystica030209 endocrinology & metabolismRisk Assessment[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system03 medical and health sciences0302 clinical medicineRare DiseasesRheumatologymedicineHumansVitamin DComputingMilieux_MISCELLANEOUS030203 arthritis & rheumatologybusiness.industryJoint boneMiddle Agedmedicine.diseaseNephrocalcinosisTreatment OutcomeCalciumRadiologybusinessTomography X-Ray Computed
researchProduct